GlassScriptPhysician profile
Adriana Spanova
NPI 1548470131
$16,188.47
in general payments reported to CMS, 2019-2025
57 companies · $3,414 in 2025
The $3,414 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $1,993 · 2021: $2,725 · 2022: $1,750 · 2023: $2,428 · 2024: $2,470 · 2025: $3,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,312.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,481.46 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,569.65 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,226.61 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,201.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,106.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.11 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $918.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $718.08 | 2019-2025 | Trintellix, Glassia |
| Amgen INC. | $581.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $528.65 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $414.81 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $353.74 | 2019-2021 | |
| Exact Sciences Corporation | $352.74 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $343.80 | 2021-2025 | Gardasil 9, Capvaxive, Belsomra |
| Allergan, INC. | $339.91 | 2019-2020 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adriana Spanova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.